{"id":1838,"date":"2010-08-01T12:07:00","date_gmt":"2010-08-01T10:07:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2010\/fragwuerdige-stammzelltherapien-auch-in-deutschland"},"modified":"2010-08-01T12:07:00","modified_gmt":"2010-08-01T10:07:00","slug":"fragwuerdige-stammzelltherapien-auch-in-deutschland","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2010\/fragwuerdige-stammzelltherapien-auch-in-deutschland","title":{"rendered":"Fragw\u00fcrdige Stammzelltherapien auch in Deutschland"},"content":{"rendered":"<p>Die \u00dcbertragung von autologen h\u00e4matopoetischen Stammzellen geh\u00f6rt heute bei einigen malignen Krankheiten, insbesondere h\u00e4matologischen Neoplasien, zum Therapiestandard. So erm\u00f6glicht, z.B. bei Multiplem Myelom, die Transfusion autologer h\u00e4matopoetischer Stammzellen eine hoch dosierte Chemotherapie mit Melphalan, da sie zu einer schnelleren Regeneration des Knochenmarks f\u00fchrt. Transplantationen allogener h\u00e4matopoetischer Stammzellen werden z.B. im Rahmen der Behandlung von akuten [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die \u00dcbertragung von autologen h\u00e4matopoetischen Stammzellen geh\u00f6rt heute bei einigen malignen Krankheiten, insbesondere h\u00e4matologischen Neoplasien, zum Therapiestandard. So erm\u00f6glicht, z.B. bei Multiplem Myelom, die Transfusion autologer h\u00e4matopoetischer Stammzellen eine hoch dosierte Chemotherapie mit Melphalan, da sie zu einer schnelleren Regeneration des Knochenmarks f\u00fchrt. Transplantationen allogener h\u00e4matopoetischer Stammzellen werden z.B. im Rahmen der Behandlung von akuten [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[4052,1436,60,3696,4051,48,4053,68,4055,4056,1438,352,4054,1439,4049,56,2043,4050],"class_list":["post-1838","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-amyotrophe-lateralsklerose","tag-anti-parkinson-mittel","tag-apoplektischer-insult","tag-arthritis","tag-augenerkrankungen","tag-diabetes-mellitus","tag-herzerkrankungen","tag-hirninfarkt","tag-inkontinenz","tag-knochenmark","tag-m-parkinson","tag-multiple-sklerose","tag-neuropathien","tag-parkinson-syndrom","tag-rueckenmarkverletzungen","tag-schlaganfall","tag-stammzelltransplantation","tag-xcell-center"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1838","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1838"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1838\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1838"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1838"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1838"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}